Advertisement
Organisation › Details
Hema.to GmbH
hema.to is an easy-to-use software for clinical decision support for blood cancer from cytometry data using AI. hema.to makes the diagnostic workflow both faster and better, helping both diagnosticians as well as patients. hema.to is a CE-IVD, FDA registered and already in routine use by leading hematology laboratories. Founded in 2021, hema.to’s mission is to make clinical analysis of cytometry data completely objective, to enable doctors to personalize treatment to their patient’s unique immune system. *
Start | 2021-10-19 established | |
Industry | AI-based diagnostics | |
Region | München (Munich) | |
Country | Germany | |
Street | 22 Ainmillerstr. | |
City | 80801 München | |
Address record changed: 2023-07-03 | ||
Basic data | Employees | n. a. |
* Document for »About Section«: High-Tech Gründerfonds Management GmbH. (6/26/23). "Press Release: Hema.to Raises €3.6M to Bring Precision Diagnostics to Immune Medicine Using AI-assisted Analysis of Single-cell Blood Data". | ||
Record changed: 2023-12-30 |
Advertisement
More documents for Hema.to GmbH
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)
Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)
Advertisement
» top